Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)

BACKGROUND: Patients with advanced chordoma are often treated with tyrosine kinase inhibitors without any predictive factor to guide decision. We report herein an ancillary analysis of the the Angionext phase II trial (NCT 00874874). RESULTS: From May 2011 to January 2014, 26 were sampled. The 9-mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebellec, Loic, Bertucci, François, Tresch-Bruneel, Emmanuelle, Bompas, Emmanuelle, Toiron, Yves, Camoin, Luc, Mir, Olivier, Laurence, Valerie, Clisant, Stephanie, Decoupigny, Emilie, Blay, Jean-Yves, Goncalves, Anthony, Penel, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342029/
https://www.ncbi.nlm.nih.gov/pubmed/27659533
http://dx.doi.org/10.18632/oncotarget.12172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342029/
https://www.ncbi.nlm.nih.gov/pubmed/27659533
http://dx.doi.org/10.18632/oncotarget.12172

Ejemplares similares